OBJECTIVES: To determine the prevalence of life-time domestic violence by the current partner before HIV-1 testing, its impact on the uptake of prevention of mother-to-child transmission (PMTCT) interventions and frequency after testing. DESIGN: A prospective cohort. METHODS: Antenatally, women and their partners were interviewed regarding physical, financial, and psychological abuse by the male partner before HIV-1 testing and 2 weeks after receiving results. RESULTS: Before testing, 804 of 2836 women (28%) reported previous domestic violence, which tended to be associated with increased odds of HIV-1 infection [univariate odds ratio (OR) 1.7, 95% confidence interval (CI) 1.3-2.2; P < 0.0001, adjusted OR 1.2, 95% CI 0.9-1.6; P = 0.1], decreased odds of coming with partners for counseling (adjusted OR 0.7, 95% CI 0.5-1.0; P = 0.04), and decreased odds of partner notification (adjusted OR 0.7, 95% CI 0.5-1.1; P = 0.09). Previous domestic violence was not associated with a reduced uptake of HIV-1 counseling, HIV-1 testing, or nevirapine. After receiving results, 15 out of 1638 women (0.9%) reported domestic violence. After notifying partners of results, the odds of HIV-1-seropositive women reporting domestic violence were 4.8 times those of HIV-1-seronegative women (95% CI 1.4-16; P = 0.01). Compared with women, men reported similar or more male-perpetrated domestic violence, suggesting a cultural acceptability of violence. CONCLUSION: Domestic violence before testing may limit partner involvement in PMTCT. Although infrequent, immediate post-test domestic violence is more common among HIV-1-infected than uninfected women. Domestic violence prevention programmes need to be integrated into PMTCT, particularly for HIV-1-seropositive women.
OBJECTIVES: To determine the prevalence of life-time domestic violence by the current partner before HIV-1 testing, its impact on the uptake of prevention of mother-to-child transmission (PMTCT) interventions and frequency after testing. DESIGN: A prospective cohort. METHODS: Antenatally, women and their partners were interviewed regarding physical, financial, and psychological abuse by the male partner before HIV-1 testing and 2 weeks after receiving results. RESULTS: Before testing, 804 of 2836 women (28%) reported previous domestic violence, which tended to be associated with increased odds of HIV-1 infection [univariate odds ratio (OR) 1.7, 95% confidence interval (CI) 1.3-2.2; P < 0.0001, adjusted OR 1.2, 95% CI 0.9-1.6; P = 0.1], decreased odds of coming with partners for counseling (adjusted OR 0.7, 95% CI 0.5-1.0; P = 0.04), and decreased odds of partner notification (adjusted OR 0.7, 95% CI 0.5-1.1; P = 0.09). Previous domestic violence was not associated with a reduced uptake of HIV-1 counseling, HIV-1 testing, or nevirapine. After receiving results, 15 out of 1638 women (0.9%) reported domestic violence. After notifying partners of results, the odds of HIV-1-seropositivewomen reporting domestic violence were 4.8 times those of HIV-1-seronegative women (95% CI 1.4-16; P = 0.01). Compared with women, men reported similar or more male-perpetrated domestic violence, suggesting a cultural acceptability of violence. CONCLUSION: Domestic violence before testing may limit partner involvement in PMTCT. Although infrequent, immediate post-test domestic violence is more common among HIV-1-infected than uninfected women. Domestic violence prevention programmes need to be integrated into PMTCT, particularly for HIV-1-seropositivewomen.
Authors: Suzanne Maman; Jessie K Mbwambo; Nora M Hogan; Gad P Kilonzo; Jacquelyn C Campbell; Ellen Weiss; Michael D Sweat Journal: Am J Public Health Date: 2002-08 Impact factor: 9.308
Authors: C Kilewo; A Massawe; E Lyamuya; I Semali; F Kalokola; E Urassa; M Giattas; F Temu; K Karlsson; F Mhalu; G Biberfeld Journal: J Acquir Immune Defic Syndr Date: 2001-12-15 Impact factor: 3.731
Authors: Y Nebié; N Meda; V Leroy; L Mandelbrot; S Yaro; I Sombié; M Cartoux; S Tiendrébeogo; B Dao; A Ouangré; B Nacro; P Fao; O Ky-Zerbo; P Van de Perre; F Dabis Journal: J Acquir Immune Defic Syndr Date: 2001-12-01 Impact factor: 3.731
Authors: Carey Farquhar; James N Kiarie; Barbra A Richardson; Marjory N Kabura; Francis N John; Ruth W Nduati; Dorothy A Mbori-Ngacha; Grace C John-Stewart Journal: J Acquir Immune Defic Syndr Date: 2004-12-15 Impact factor: 3.731
Authors: Patricia J Kissinger; Linda M Niccolai; Manya Magnus; Thomas A Farley; Julie E Maher; Gwangi Richardson-Alston; Dennis Dorst; Leann Myers; Thomas A Peterman Journal: Sex Transm Dis Date: 2003-01 Impact factor: 2.830
Authors: Kristin L Dunkle; Rachel K Jewkes; Heather C Brown; Glenda E Gray; James A McIntryre; Siobán D Harlow Journal: Lancet Date: 2004-05-01 Impact factor: 79.321
Authors: Marielle S Goyette; Peter M Mutiti; David Bukusi; Beatrice M Wamuti; Felix A Otieno; Peter Cherutich; Matthew R Golden; Hans Spiegel; Barbra A Richardson; Anne Ngʼangʼa; Carey Farquhar Journal: J Acquir Immune Defic Syndr Date: 2018-05-01 Impact factor: 3.731
Authors: Carolyn M Audet; Meridith Blevins; Yazalde Manuel Chire; Muktar H Aliyu; Lara M E Vaz; Elisio Antonio; Fernanda Alvim; Ruth Bechtel; C William Wester; Sten H Vermund Journal: AIDS Behav Date: 2016-09
Authors: Elijah O Onsomu; Benta A Abuya; Irene N Okech; David L Rosen; Vanessa Duren-Winfield; Amber C Simmons Journal: Health Care Women Int Date: 2014-10-08
Authors: Abigail M Hatcher; Patrizia Romito; Merab Odero; Elizabeth A Bukusi; Maricianah Onono; Janet M Turan Journal: Cult Health Sex Date: 2013-02-06